Summary
By gathering an initial collection of 680 public Sequence Read Archives from the Mycobacterium tuberculosis complex (MTC) including 190 belonging to the lineage 2 Beijing, and using a new bioinformatical pipeline, TB-Annotator, that analyzes more than 50,000 characters, we characterized a phylogenetically significant L2 sublineage from isolates found in Tochigi province, that we designate as Asia Ancestral 5. These isolates harbor a number of specific criteria (42 specific SNPs) and their intra-cluster pairwise distance suggested historical and not epidemiological transmission. These isolates harbor a mutation in rpoC, and do not fulfill, either the Modern Beijing lineage criteria (L2.2.1.2.2) or the other currently known Ancestral Beijing lineages described so far. Asia Ancestral 5 isolates do not possess mutT2 58 and ogt 12 characteristics of Modern Beijing, but possess ancient evolutionary characteristics. By looking into the literature, we found in a reference isolate ID381, found in Kobe and Osaka, and defined as “G3”, 36 out of 42 shared and specific SNPs in the same sublineage. Using this study, we also confirmed the intermediate position of the Asia Ancestral 4 recently described in Thailand and suggest an improved classification of the L2 that now includes Asia Ancestral 4 and 5. Increasing the recruitment to around 3000 genomes (including 642 belonging to L2) confirmed our results and suggest new historical ancestral L2 phylogenetically relevant branches that remain to be investigated in detail. We discuss some anthropological and historical data from Japan history and its link to Korea and China. This study shows that the reconstruction of the early history of tuberculosis pandemia in Asia is likely to reveal complex patterns since its emergence.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study did not receive specific funding. The authors declare that they have no conflict of interest.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Not Applicable
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data are publicly available or contained in the article as supplementary files.
